They sold 2 mil because that's what LPC offered, with 25mil of shares to be financed at Nuvilex request at near market prices. They don't need the entire 27mil not nor would LPC invest that much before trials complete. This basically makes it so as long as trial data is good they have the capital to continue as planned without diluting which is huge for a smaller bio tech company.
News 
Market Data 
Discover 
AI
